CD44 and glioblastoma: Moreover, Hartheimer et al. determined how hyaluronidases can sensitize GBM stem cells to chemotherapy drugs by disrupting the HA-CD44 signaling, with which they further developed a combined treatment of hyaluronidases and chemotherapy drugs by disrupting the stemness-promoting HA to target GBM stem cells.